Predicting the molecular subtypes of breast cancer using nomograms based on three-dimensional ultrasonography characteristics

Xiaojing Xu, Liren Lu, Luoxi Zhu, Yanjuan Tan, Lifang Yu and Lingyun Bao*
Department of Ultrasound, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background: Molecular subtyping of breast cancer is commonly done for individualized cancer management because it may determines prognosis and treatment. Therefore, preoperatively identifying different molecular subtypes of breast cancer can be significant in clinical practice. This retrospective study aimed to investigate characteristic three-dimensional ultrasonographic imaging parameters of breast cancer that are associated with the molecular subtypes and establish nomograms to predict the molecular subtypes of breast cancers.

Methods: A total of 309 patients diagnosed with breast cancer between January 2017 and December 2019 were enrolled. Sonographic features were compared between the different molecular subtypes. A multinomial logistic regression model was developed, and nomograms were constructed based on this model.

Results: The performance of the nomograms was evaluated in terms of discrimination and calibration. Variables such as maximum diameter, irregular shape, non-parallel growth, heterogeneous internal echo, enhanced posterior echo, lymph node metastasis, retraction phenomenon, calcification, and elasticity score were entered into the multinomial model. Three nomograms were constructed to visualize the final model. The probabilities of the different molecular subtypes could be calculated based on these nomograms. Based on the receiver operating characteristic curves of the model, the macro- and micro- area under the curve (AUC) were 0.744, and 0.787. The AUC was 0.759, 0.683, 0.747 and 0.785 for luminal A (LA), luminal B (LB), human epidermal growth factor receptor 2-positive (HER2), and triple-negative (TN), respectively. The nomograms for the LA, HER2, and TN subtypes provided good calibration.

Conclusions: Sonographic features such as calcification and posterior acoustic features were significantly associated with the molecular subtype of breast cancer.
cancer. The presence of the retraction phenomenon was the most important predictor for the LA subtype. Nomograms to predict the molecular subtype were established, and the calibration curves and receiver operating characteristic curves proved that the models had good performance.

**KEYWORDS**
breast cancer, molecular subtypes, ultrasonography, relevance of three-dimensional ultrasonography, nomogram

**Introduction**
Breast cancer is a heterogeneous and complex disease. The main molecular subtypes of breast cancer are luminal A (LA), luminal B (LB), human epidermal growth factor receptor2-positive (HER2), and triple-negative (TN) (1, 2). This heterogeneity leads to vast differences in disease progression, treatment response, and prognosis. Therefore, preoperatively identifying different molecular subtypes of breast cancer can be significant in clinical practice. Nomograms have been used extensively for visualizing predictive models in cancer. They present user-friendly graphic presentation of the estimated probabilities of the molecular subtypes. Moreover, nomograms may guide clinical diagnosis and treatment and can help facilitate precision medicine (3).

Hand-held ultrasonography (HHUS) has some limitations because of the lack of standardization (4). Meanwhile, three-dimensional ultrasonography (3D-US) has been essential as a preoperative tool because of its reproducibility and reduced operator dependence. Furthermore, its unique coronal plane can provide additional diagnostic information and potentially improve the characterization of breast lesions. Moreover, the availability of automated breast US in clinical practice is increasing (5, 6). Determining whether preoperative 3D-US can distinguish tumour subtypes has important clinical significance. Previous studies have shown that the characteristics of 3D-US correlated with molecular classification, for example, calcification is associated with the HER2-positive subtype, while the retraction phenomenon is more related to the LA subtype (7–9).

In recent years, artificial intelligence for 3D-US has been applied in the differential diagnosis of benign and malignant breast masses, however there are only a studies on 3D-US in molecular typing (10).

The study aimed to investigate the relevance of the 3D-US imaging characteristics of breast cancer associated with specific molecular subtypes in order to establish nomograms that distinguish the molecular subtypes of breast cancer. This study explored the possibility of predicting molecular typing models with large samples and provided insights into the future artificial intelligence prediction of molecular typing.

**Methods**

**Patients**
The Institutional Review Board authorized this retrospective study. The requirement for informed consent was waived due to the retrospective nature of the study. Between January 2017 and December 2019, 326 patients were consecutively enrolled from our hospital with random selection. All patients had invasive breast cancer, which was histologically diagnosed. Their molecular subtypes were estimated from the surgical specimens. Patients with lesions of undetermined immunohistochemical results (n=12) and patients with considerable deformity of the breast or chest (n=5) were excluded. After these exclusions, 309 patients were enrolled in this study.

**Data collection**
Patient information and lesion size and location were recorded. All imaging features were retrospectively reviewed according to the 5th edition of the American College of Radiology Breast Imaging Reporting and Data System lexicon (11). Two radiologists who were blinded to the patients' previous imaging data and clinical information, age, tumor position, and maximum tumor diameter (according to the TNM[tumor, node, metastasis] stage, the maximum diameter stratifications were (<2cm, 2–5cm, and >5cm) reviewed the volume data on an automated breast volume scanner (ABVS) workstation (Siemens Medical Solutions, Mountain View, CA, USA). Analysis of mass lesions included shape (regular or irregular),

---

**Abbreviations:** 3D-US, three-dimensional ultrasonography; ABVS, automated breast volume scanner; AUC, area under the curve; ER, estrogen receptor; HER2, human epidermal growth factor receptor; HHUS, hand-held ultrasonography; LA, luminal A; LB, luminal B; PR, progesterone receptor; ROC, receiver operating characteristic; TN, triple-negative.
lesion type (mass or no-mass [no-mass refers to a hypoechoic area lacking a conspicuous margin or shape and can be defined as a non space-occupying lesion]) (12), margin (circumscribed or non-circumscribed), non-parallel/parallel growth, echogenicity (hypoechoic, isoechoic, hyperechoic, or complex), post-acoustic features (enhancement, shadowing, mixed, or no change), calcification types, and axillary lymph node metastasis (round shape, or irregular shape, cortical thickening, asymmetric cortical thickness ≥3 mm, hilar compression, or displacement).

Coronal features included the retraction phenomenon and the skipping sign. The retraction phenomenon was defined as the convergence tendency of the tissue surrounding a lesion with or without cord-like hyperechogenicity intervals on the coronal plane. The skipping sign was defined as anechoic lines around the lesion (13). Elasticity scores were recorded using strain elastography (Tsukuba score, 5 points) (14).

Molecular subtypes were defined according to the 2015 revised St. Gallen International Expert Consensus Recommendation (15). Immunohistochemical staining was performed to examine estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 expression. Molecular subtypes were diagnosed according to their hormone receptor and HER2 status, as follows: LA: ER+, PR+, HER2-, and low Ki-67 index; LB: ER+, PR+ or PR-, HER2- or HER2+, and high Ki-67 index; HER2: ER-, PR-, and HER2+; and TN: ER-, PR-, and HER2-. The Ki-67 index was classified as high when ≥14% of the tumor cells were immunostained (16).

Statistical analysis

R software version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses. Statistical significance was set at p<0.05. Nomograms were developed in four steps. First, single factors were compared between the different molecular types using the χ² test (parametric) or Fisher’s exact test (non-parametric). The factors of the entire dataset were compared between groups, and the p values were calculated. Second, factors with p<0.05 were included in the establishment of a four-category prediction model, and a multi-classification regression model was established using multinomial logistic regression for the entire dataset. Third, nomograms were constructed based on the results of the multivariate logistic regression model (17). The total scores of each patient were calculated based on the nomograms, and the probabilities of the LB, HER2, and TN molecular subtypes, with the LA subtype as a reference, were calculated based on these nomograms. Fourth, the performance of the nomograms was evaluated in terms of discrimination and calibration. Calibration curves were used to observe the consistency between the predicted and the true values. The predictive performance of the nomograms was measured using the concordance index and calibration with 1000 bootstrap samples was performed to decrease the overfit bias.

Results

General characteristics of the study population

The average age of the study population was 54.25 ± 11.18 years, ranging from 25 to 85 years. There were 288 cases of invasive ductal carcinoma and 21 cases of special types of invasive breast cancer. The general characteristics of the study population, including height, weight, type II diabetes status, and hypertension, are shown in Table 1. LB was the most common of the four molecular subtypes (n=137, 44.3%), and LA was the second most common (n = 82, 26.6%). The HER2 and TN subtypes were less common (n=40, 12.9% and n=50, 16.2%, respectively).

| Variables       | Patients with breast cancer (n=309) |
|-----------------|-------------------------------------|
| Age (years, mean ± SD) | 54.25 ± 11.18                  |
| Height (cm, mean ± SD)   | 159.08 ± 4.33       |
| Weight (kg, mean ± SD)   | 60.25 ± 8.78        |
| Sex              | Female 309 (100.0)          |
| Type2 diabetes    | no 286 (92.6)               |
|                  | yes 23 (7.4)                |
| Hypertension      | no 227 (73.5)               |
|                  | yes 82 (26.5)               |
| Mastectomy        | total 263 (85.1)            |
|                  | partial 46 (14.9)           |
| Tumor type        | IDC 288 (93.2)              |
|                  | others 21 (6.8)             |
| Histological grade | I 21 (6.8)                  |
|                  | II 135 (43.7)               |
|                  | III 132 (42.7)              |
| Molecular subtype | LA 82 (26.5)                |
|                  | LB 137 (44.3)               |
|                  | HER2 40 (12.9)              |
|                  | TN 50 (16.2)                |

SD, standard deviation; IDC, invasive ductal carcinoma; LA, luminal A; LB, luminal B; HER2, human epidermal growth factor receptor 2; TN, triple-negative.
Differences in clinicopathological characteristics, 3D-US features, and coronal features among the molecular subtypes

There was no significant difference in age and maximum diameter among the four subtypes. However, the maximum diameter stratifications (<2cm, 2–5cm, and >5cm) showed statistical significance. On-mass lesions cannot be expressed in terms of mass description, therefore ‘NA’(no answer) is entered in the table. The detailed distributions of the histologic types are shown in Table 2.

Multifactor multiclass logistic regression analysis

Variables with \( p < 0.05 \) in the single-factor analysis were entered into the model. These included maximum diameter, irregular shape, non-parallel growth, heterogeneous internal echo, enhanced posterior echo, lymph node metastasis, retraction phenomenon, calcification, and elasticity score.

Construction of three nomograms to visualize the final model

Three nomograms were created to predict the probabilities of the LB, HER2-positive, and TN subtypes. Each independent variable value corresponded to a point value on the top row, and the individual scores were added to yield the total score. The probability was then calculated based on the total score (15). The results are shown in Figures 1–3. Receiver operating characteristic (ROC) curves were established to assess the accuracy of the model (Figure 4). The macro- and micro-AUC were 0.744 and 0.787, respectively. The AUC was 0.759 for predicting LA, 0.683 for predicting LB, 0.747 for predicting HER2-positive, and 0.785 for predicting TN. Calibration curves were also constructed. The closer the calibration curve (black) is to the standard curve (red), the better the calibration capability of the model. The model had good calibration for the LA, HER2, and TN subtypes, as shown in Figure 5.

Discussion

US is the most widely used auxiliary examination technique for the preoperative evaluation of breast cancer. However, certain errors may occur during the preoperative puncture, which can have adverse effects. Therefore, identifying the molecular classification of breast cancer is vital to guide the selection of an individualized clinical plan. Moreover, it is difficult to utilize the traditional classification for these treatment plans. Therefore, establishing a model that incorporates multiple factors to identify the molecular subtype can be used to predict the risk of mortality and facilitate the implementation of individualized treatment (18, 19). Since the ultrasonography features of different molecular types overlap, it is more appropriate to use a multivariate prediction model. The model in this study uses more parameters, thereby avoiding the limitations of single-parameter evaluation. The nomograms created here integrated relevant factors that affect molecular typing in a simple graphical manner, allowing clinicians and patients to understand the relationship between various factors and molecular typing. Given a set of known quantitative conditions, they can easily calculate the probability value of the corresponding outcome (20). Therefore, the realization of individualized classification prediction is in line with the pursuit of individualized treatment.

LA and LB cancers account for approximately 70% of breast cancer cases (21). Similar findings were observed in this cohort, where these subtypes accounted for 72.8% of cases (LA: 26.6% and LB: 44.3%). Therefore, the distribution of molecular subtypes in this single-center study is consistent with those in other studies with larger samples.

ABVS is a 3D-US imaging system that overcomes the main shortcomings of HHUS, such as lack of standardization, non-repeatability, small field of view, and excessive time investment. Additionally, for women with dense breast tissue, ABVS can recognize calcification and the retraction phenomenon more due to its unique coronal reconstruction. Furthermore, ABVS is more accurate than HHUS in assessing the extent of the disease, average lesion size (22), and largest diameter (23). Hence, it can better assess the true scope of the disease. Recent studies have also shown that the imaging features acquired by ABVS are related to the molecular subtypes of breast cancer. In this study, there was a significant difference among the four molecular subtypes in the maximum diameter of the tumor. Patients with the LA subtype had tumors<2cm, whereas in patients with other subtypes, the largest diameter was 2–5cm. The HER2 molecular subtype had more calcification than the other subtypes. The retraction phenomenon was more likely to be seen in the LA subtype than in any other subtypes. The TN subtype did not display the retraction phenomenon or post-acoustic enhancement. In the LA subtype, the body has more time to respond to cancer cells and form fibrosis, which leads to a contraction pattern (24, 25). Since ABVS has these advantages, it is more useful in evaluating breast cancer preoperatively.

A nomogram is a graphical calculation model that uses known predictive factors to calculate the numerical probability of a clinical event. Such prediction models are valuable. A multivariate logistic regression model we constructed via stepwise analysis, nomograms were subsequently developed based on the fitted multivariate logistic regression model.
### Table 2: Clinicopathological characteristics of patients with different molecular subtypes.

| Variables                                | LA (n=82) | LB(n=137) | HER2 (n=40) | TN (n=50) | p       | test |
|------------------------------------------|-----------|-----------|-------------|-----------|---------|------|
| Age (years, mean ± SD)                   | 55.65 ± 11.00 | 54.37 ± 11.27 | 52.80 ± 9.68 | 52.78 ± 12.30 | 0.420   | ANOVA |
| Age                                       |           |           |             |           | 0.398   |      |
| <60 years                                 | 51 (62.2) | 90 (65.7) | 28 (70.0)   | 38 (76.0) |         |      |
| ≥60 years                                 | 31 (37.8) | 47 (34.3) | 12 (30.0)   | 12 (24.0) |         |      |
| Maximum diameter (cm, mean ± SD)         | 2.11 ± 1.27 | 2.95 ± 1.92 | 3.02 ± 1.30 | 2.91 ± 1.94 | 0.002   | ANOVA |
| Maximum diameter stratification           |           |           |             |           | <0.001  | Fisher|
| <2cm                                      | 47 (57.3) | 40 (29.2) | 8 (20.0)    | 15 (30.0) |         |      |
| 2-5cm                                     | 31 (37.8) | 85 (62.0) | 28 (70.0)   | 30 (60.0) |         |      |
| >5cm                                      | 4 (4.9)   | 12 (8.8)  | 4 (10.0)    | 5 (10.0)  |         |      |
| Lesion type                               |           |           |             |           | 0.418   |      |
| no-mass                                   | 10 (12.2) | 26 (20.4) | 7 (17.5)    | 7 (14.0)  |         |      |
| mass                                      | 72 (87.8) | 109 (79.6)| 33 (82.5)   | 43 (86.0) |         |      |
| Location                                  |           |           |             |           | 0.640   |      |
| left                                      | 42 (51.2) | 64 (46.7) | 23 (57.5)   | 25 (50.0) |         |      |
| right                                     | 40 (48.8) | 73 (53.3) | 17 (42.5)   | 25 (50.0) |         |      |
| Irregular mass                            |           |           |             |           | 0.068   | Fisher|
| no                                        | 71 (86.6) | 104 (75.9)| 32 (80.0)   | 36 (72.0) |         |      |
| yes                                       | 1 (1.2)   | 7 (5.1)   | 1 (2.5)     | 7 (14.0)  |         |      |
| NA                                        | 10 (12.2) | 26 (19.0) | 7 (17.5)    | 7 (14.0)  |         |      |
| Non-circumscribed margin                  |           |           |             |           | 0.123   | Fisher|
| no                                        | 72 (87.8) | 106 (77.4)| 33 (82.5)   | 39 (78.0) |         |      |
| yes                                       | 0 (0.0)   | 5 (3.6)   | 0 (0.0)     | 4 (8.0)   |         |      |
| NA                                        | 10 (12.2) | 26 (19.0) | 7 (17.5)    | 7 (14.0)  |         |      |
| Non-parallel mass                         |           |           |             |           | 0.064   |      |
| no                                        | 49 (59.8) | 84 (61.3) | 26 (65.0)   | 40 (80.0) |         |      |
| yes                                       | 23 (28.0) | 27 (19.7) | 7 (17.5)    | 3 (6.0)   |         |      |
| NA                                        | 10 (12.2) | 26 (19.0) | 7 (17.5)    | 7 (14.0)  |         |      |
| Echogenicity                              |           |           |             |           | 0.004   | exact |
| complex                                   | 4 (4.9)   | 6 (4.4)   | 1 (2.5)     | 8 (16.0)  |         |      |
| hyperechoic                               | 2 (2.4)   | 0 (0.0)   | 0 (0.0)     | 0 (0.0)   |         |      |
| isoechoic                                 | 0 (0.0)   | 0 (0.0)   | 1 (2.5)     | 0 (0.0)   |         |      |
| heterogeneous                              | 20 (24.4) | 48 (35.0) | 17 (42.5)   | 10 (20.0) |         |      |
| hypoechoic                                | 46 (56.1) | 57 (41.6) | 14 (35.0)   | 25 (50.0) |         |      |
| NA                                        | 10 (12.2) | 26 (19.0) | 7 (17.5)    | 7 (14.0)  |         |      |
| Post-acoustic features                    |           |           |             |           | 0.016   |      |
| enhance                                   | 14 (17.1) | 26 (19.0) | 15 (37.5)   | 18 (36.0) |         |      |
| shadowing                                 | 27 (32.9) | 31 (22.6) | 8 (20.0)    | 6 (12.0)  |         |      |
| mix                                       | 2 (2.4)   | 6 (4.4)   | 3 (7.5)     | 5 (10.0)  |         |      |
| no-change                                 | 29 (35.4) | 48 (35.0) | 7 (17.5)    | 14 (28.0) |         |      |
| NA                                        | 10 (12.2) | 26 (19.0) | 7 (17.5)    | 7 (14.0)  |         |      |
| Calcification                             |           |           |             |           | <0.001  |      |
| no                                        | 52 (63.4) | 50 (36.5) | 10 (25.0)   | 29 (58.0) |         |      |
| yes                                       | 30 (36.6) | 87 (63.5) | 30 (75.0)   | 21 (42.0) |         |      |
| Lymph node metastasis                     |           |           |             |           | 0.029   |      |
| no                                        | 59 (72.0) | 75 (54.7) | 23 (57.5)   | 36 (72.0) |         |      |
| yes                                       | 23 (28.0) | 62 (45.3) | 17 (42.5)   | 14 (28.0) |         |      |
| Retraction phenomenon                     |           |           |             |           | 0.001   |      |

(Continued)
calcification, post-acoustic enhancement, and the retraction phenomenon were used to construct the nomogram model for distinguishing the molecular subtype of breast cancer. The scores of the influencing factors could show the individualized prediction results. The discriminative power of the nomogram was quantified using the AUC, exhibiting the accuracy of the test. Previous studies have shown that models with AUCs of 0.5–0.7 have low predictive value, models with AUCs of 0.7–0.85 have better predictive value, and models with AUCs of 0.85–0.95 have the best predictive value (26). The model in this study has AUCs of 0.68–0.78, indicating that the prediction model had a good degree of discrimination. The nomograms also contained information for clinical use; therefore, they might serve as tools to calculate the probabilities of the various molecular subtypes.

Recent studies have developed models to predict the molecular classification of breast cancer through radiomics or machine learning approaches using image segmentation (27, 28). These generally employ two-dimensional US modelling for a single molecular classification or deep learning magnetic resonance image modeling. Although these have been shown to be predictive, the feature extraction is complicated and has certain limitations. Compared with HHUS, ABVS allows the

| Variables           | Molecular subtype | p     | test |
|---------------------|-------------------|-------|------|
|                     | LA (n=82)         | LB(n=137) | HER2 (n=40) | TN (n=50) |
| no                  | 34 (41.5)         | 72 (52.6) | 27 (67.5) | 37 (74.0) |
| yes                 | 48 (58.5)         | 65 (47.4) | 13 (32.5) | 13 (26.0) |
| Skipping sign       |                   |        | 0.682 | χ²   |
| no                  | 56 (68.3)         | 87 (63.5) | 24 (60.0) | 35 (70.0) |
| yes                 | 26 (31.7)         | 50 (36.5) | 16 (40.0) | 15 (30.0) |
| Elasticity score    |                   |        | 0.023 | χ²   |
| 3                   | 11 (13.4)         | 18 (13.1) | 3 (7.5)  | 10 (20.0) |
| 4                   | 42 (51.2)         | 64 (46.7) | 22 (55)  | 34 (68.0) |
| 5                   | 29 (35.4)         | 55 (40.2) | 15 (37.5) | 6 (12.0)  |

NA (not available) represents missing values.
LA, luminal A; LB, luminal B; HER2, human epidermal growth factor receptor 2; TN, triple-negative; SD, standard deviation; ANOVA, analysis of variance.

![FIGURE 1](link)

**FIGURE 1**
LB prediction nomogram. Nomograms were constructed based on the results of the multivariate logistic regression mode factors.
use of computer-aided design (29) and artificial intelligence technology to improve the diagnostic performance of deep machine learning due to its repeatability and image storage method. 3D-US may potentially be useful in the field of artificial intelligence, however, this needs further verification. This study predicted the four molecular classifications using only 3D-US features. Nomograms were also used to visualize the predictive multinomial model of the molecular classifications.

The study has several limitations. First, this was a retrospective study performed at a single institution. A multicenter prospective study with a large sample size needs to be performed to validate this study’s results. Second, the sample
FIGURE 4
ROC curve. The macro- and micro-AUC were 0.744 and 0.787, respectively. The AUC was 0.759 for predicting LA, 0.683 for predicting LB, 0.747 for predicting HER2-positive, and 0.785 for predicting TN.

FIGURE 5
Calibration curve of the nomogram. The diagonal line indicates the ideal nomogram reference.
sizes of the four molecular subtypes were unbalanced. As a result, the ROC curves of subtypes with fewer samples are unsatisfactory. Further studies should consider having balanced sample sizes.

Conclusions

In conclusion, sonographic features such as calcification and posterior acoustic features were significantly associated with the breast cancer molecular subtypes. In addition, the presence of the retraction phenomenon was the most important predictor for the LA subtype. Nomograms for the prediction of the molecular subtypes were established based on the results of the multifactor analysis. The calibration and ROC curves showed that the model had good performance. Further multicenter studies will be useful for updating and validating these nomograms to improve the predictions of molecular subtypes.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Hangzhou First people’s Hospital ethics committee. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

LB contributions to design of the work. YT and LY analysis of data for the work, XX and LL, drafting the work. LZ revising the work critically for important intellectual content. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

The study was supported by The Construction Fund of Medical Key Disciplines of Hangzhou.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Çelebi F, Pilanci KN, Ordu Ç, Ağçayak F, Alço G, Iğün S, et al. The role of ultrasonographic findings to predict molecular subtype, histologic grade, and hormone receptor status of breast cancer. DiagnIntervRadiol (2015) 21:448–53. doi: 10.5152/dir.2015.14515
2. Choi WJ, Cha JH, Kim HI, Shin HJ, Chae EY. Accuracy of breast MR imaging for measuring the size of a breast cancer: analysis of the histopathologic factors. Clin Breast Cancer (2016) 16:e145–152. doi: 10.1016/j.clbc.2016.07.007
3. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J ClinOncol (2008) 26:1364–70. doi: 10.1200/JCO.2007.12.9791
4. Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagöz O, et al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2015) 162:157–66. doi: 10.7326/M14-0692
5. van Zelst ICM, Balkenhol M, Tan T, Rutten M, Imhof-Tas M, Bult P, et al. Sonographic phenotypes of molecular subtypes of invasive ductal cancer in automated 3-d breast ultrasound. Ultrasound Med Biol (2017) 43:1820–8. doi: 10.1016/j.ultrasmedbio.2017.03.019
6. Vourtsis A, Kachulis A. The performance of 3D ABUS versus HHUS in the visualisation and BI-RADS characterisation of breast lesions in a large cohort of 1,886 women. EurRadiol (2018) 28:592–601. doi: 10.1007/j.ectr.2018.02.014
7. Rella R, Belli P, Giuliani M, Buﬁ E, Carlino G, Rinaldi P, et al. Automated breast ultrasonography (ABUS) in the screening and diagnostic setting: Indications and practical use. AcadRadiol (2018) 25:1457–70. doi: 10.1016/j.acra.2018.02.014
8. Kim SH, Kim HH, Moon WK. Automated breast ultrasound screening for dense breasts. Korean J Radiol (2020) 21:15–24. doi: 10.3348/kjr.2019.0176
9. Vourtsis A. Three-dimensional automated breast ultrasound: Technical aspects and first results. DiagInterv Imaging (2019) 100:579–92. doi: 10.1016/j.diii.2019.03.012
10. Nicolis L, Ferrari F, Rozzini AC, Latronico A, Trentin C, Meneghetti L, et al. Automatic breast ultrasound: state of the art and future perspectives. Eancermedecine (2020) 14:1062. doi: 10.3332/ecancer.2020.1062
11. Mendelson EB, Böhm-Velez M, Berg WA, Whitman G, Feldman M, Madjar H. ACR BI-RADS® atlas. Breast imaging reporting and data system. Reston, VA: American College of Radiology (2013).
12. Uematsu T. Non-mass-like lesions on breast ultrasonography: a systematic review. *Breast Cancer* (2012) 19:295–301. doi: 10.1007/s12282-012-0364-z

13. Tang G, An X, Xiang H, Liu L, Li A, Lin X. Automated breast ultrasound: Interobserver agreement, diagnostic value, and associated clinical factors of coronal-plane image features. *Korean J Radiol* (2020) 21:550–60. doi: 10.3348/kjr.2019.0525

14. Barr RG, Nakashima K, Amy D, Cosgrove D, Farrokh A, Schafer F, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2: breast. *Ultrasound Med Biol* (2015) 41:1148–60. doi: 10.1016/j.ultrasmedbio.2015.03.008

15. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. *Ann Oncol* (2015) 26::1533–46. doi: 10.1093/annonc/mdv221

16. García-Fernández A, Chabrera C, García Font M, Fraile M, Lain JM, González S, et al. Differential patterns of recurrence and specific survival between luminal a and luminal b breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification. *Clin Transl Oncol* (2015) 17:238–46. doi: 10.1007/s12094-014-1220-8

17. Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. *J Urol* (2008) 179::2207–10; discussion 2210-1. doi: 10.1016/j.juro.2008.01.106

18. Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS. Breast cancer genomics from microarrays to massively parallel sequencing: Paradigms and new insights. *J Natl Cancer Inst* (2015) 107::dy5. doi: 10.1093/jnci/dy5

19. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* (2012) 490:61–70. doi: 10.1038/nature11412

20. Ardoino I, Lanzoni M, Marano G, Boracchi P, Sagrini E, Gianstefani A, et al. Widen Nomogram for multinomial logistic regression: An application to staging liver fibrosis in chronic hepatitis c patients. *Stat Methods Med Res* (2017) 26:823–38. doi: 10.1177/0962280214560045

21. Cho N. Molecular subtypes and imaging phenotypes of breast cancer. *Ultrasonography* (2016) 35:281–8. doi: 10.14366/usg.16030

22. Huang A, Zhu L, Tan Y, Liu J, Xiang J, Zhu Q. Evaluation of automated breast volume scanner for breast conservation surgery in ductal carcinoma in situ. *Oncol Lett.* (2016) 12:2481–4. doi: 10.3892/ol.2016.4924

23. Li N, Jiang YX, Zhu QL, Zhang J, Dai Q, Liu H, et al. Accuracy of an automated breast volume ultrasound system for assessment of the pre-operative extent of pure ductal carcinoma in situ: comparison with a conventional handheld ultrasound examination. *Ultrasound Med Biol* (2013) 39:2255–63. doi: 10.1016/j.ultrasmedbio.2013.07.010

24. Huang J, Lin Q, Cui C, Fei J, Su X, Li L, et al. Correlation between imaging features and molecular subtypes of breast cancer in young women (≤30 years old). *Ipn J Radiol* (2020) 38:1062–74. doi: 10.1007/s11604-020-01001-8

25. Zheng F, Yan L, Huang B, Xia H, Wang X, Lu Q, et al. Comparison of retraction phenomenon and BI-RADS-US descriptors in differentiating benign and malignant breast masses using an automated breast volume scanner. *Eur J Radiol* (2015) 84:2123–9. doi: 10.1016/j.ejrad.2015.07.028

26. Swets JA. Measuring the accuracy of diagnostic systems. *Science* (1988) 240:1285–93. doi: 10.1126/science.3287615

27. Montemezzi S, Camera L, Giri MG, Pozzetto A, Caliò A, Meliando G, et al. Is there a correlation between 3T multiparametric MRI and molecular subtypes of breast cancer? *Eur J Radiol* (2018) 108:120–7. doi: 10.1016/j.ejrad.2018.09.024

28. Saha A, Harowicz MR, Grimm LJ, Kim CE, Ghate SV, Walsh R, et al. A machine learning approach to radiogenomics of breast cancer: A study of 922 subjects and 529 DCE-MRI features. *Br J Cancer* (2018) 119:508–16. doi: 10.1038/s41416-018-0185-8

29. Lo C, Shen YW, Huang CS, Chang RF. Computer-aided multiview tumor detection for automated whole breast ultrasound. *Ultrasound Imaging* (2014) 36:3–17. doi: 10.1177/0161734613507240